Novel Substituted Indazoles as Small Molecule-Based Inhibitors of KRAS Proteins

This patent discloses a series of substituted indazole compounds as novel inhibitors of KRAS, with potential utility as anticancer therapeutics. The invention describes the chemical structures of these substituted indazoles, their pharmaceutical compositions, and methods of use for treating KRAS-driven malignancies. The disclosed compounds are designed to modulate oncogenic KRAS signaling and may offer a new therapeutic strategy for cancers associated with KRAS mutations.